Bechini Angela, Moscadelli Andrea, Velpini Beatrice, Bonito Benedetta, Orlando Paolo, Putignano Pasqua, Posi Silvano, Stacchini Lorenzo, Bonanni Paolo, Boccalini Sara
Department of Health Sciences, University of Florence, 50134 Florence, Italy.
Department of Health Sciences, Specialization Medical School of Hygiene, University of Florence, 50134 Florence, Italy.
Vaccines (Basel). 2023 Jun 9;11(6):1084. doi: 10.3390/vaccines11061084.
Vulvar and vaginal cancers are relatively rare cancers, but their incidence is increasing worldwide. Overall, 78% of vaginal cancers and 25% of vulvar cancers are associated with Human papillomavirus (HPV) infection. Immunization could be an option for the management of these cases. We researched and assessed the evidence on the efficacy of HPV vaccination administered to women previously treated with surgery, radiotherapy, or chemotherapy with respect to the recurrence of vulvovaginal disease. From 2006 to November 2022, only one study evaluated the efficacy of HPV vaccination with respect to preventing vulvovaginal recurrences in treated women and showed that a quadrivalent HPV vaccine administered after the surgical treatment of vulvar high-grade squamous intraepithelial lesion (HSIL) can reduce vulvar recurrence of the disease. Therefore, the efficacy of HPV vaccination with respect to vulvovaginal recurrence is still an unexplored field. Further studies are needed to produce stronger evidence in order to appropriately support interventions to protect women's health.
外阴癌和阴道癌是相对罕见的癌症，但在全球范围内其发病率正在上升。总体而言，78%的阴道癌和25%的外阴癌与人乳头瘤病毒（HPV）感染有关。免疫接种可能是这些病例管理的一种选择。我们研究并评估了关于对先前接受过手术、放疗或化疗的女性接种HPV疫苗对外阴阴道疾病复发疗效的证据。从2006年到2022年11月，仅有一项研究评估了HPV疫苗接种对预防已治疗女性外阴阴道复发的疗效，结果显示在外阴高级别鳞状上皮内病变（HSIL）手术治疗后接种四价HPV疫苗可降低该疾病的外阴复发率。因此，HPV疫苗接种对外阴阴道复发的疗效仍是一个未被探索的领域。需要进一步的研究来提供更有力的证据，以便适当地支持保护女性健康的干预措施。
Zotero 插件